It has been a “hot” summer for Health Canada. The Canadian regulator of pharmaceuticals has been busy approving new laws and announcing new proposals. Many of these initiatives are linked to Canada’s overarching strategic policy priority to improve access to drugs. To make sure your summer vacation schedule didn’t cause you to miss out, we are here to summarize the latest so you can hit the ground running this fall.
Amended FDR Regulations on Shortages and Discontinuation of Sale of Drugs and Medical Devices
On June 17, 2026, Health Canada published the Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Shortages and Discontinuation of Sale of Drugs and Medical Devices) (Amending Regulations), comprising amendments to both the Food and Drug Regulations (FDR) and the Medical Devices Regulations. We previously reported on Health Canada’s proposed amendments.
The amendments are intended to strengthen Canada’s regulatory frameworks for preventing, mitigating, and responding to drugs and medical device shortages. The major changes target the following:
- Allowing the Minister of Health to expand the scope of drugs subject to the regulatory obligations for shortages to additional drugs or classes of drugs listed on the Expanded Scope List, which is incorporated by reference into the FDR.
- Allowing the minister to require the provision of information for shortages of any drug that could present a risk of injury to human health, as opposed to just drugs that fall within the scope of shortage reporting under the FDR.
- Allowing the minister to increase the supply of drugs available to address an active or anticipated shortage by extending the expiration dates for Canadian-authorized lots or batches of drugs listed on the Extended Expiration Date List, also incorporated by reference into the FDR.
- Updating Canada’s exceptional importation and sale frameworks for both drugs and medical devices to allow them to be used in a broader range of circumstances (e.g., for over-the-counter drug products).
- Requiring more notice for reporting a drug’s discontinuation: a discontinuation must be reported at least 12 months in advance of stopping sales, as opposed to the former six-month deadline.
- Simplifying when and where discontinuations and shortages of medical devices need to be reported, including introducing a designated reporting website, and repealing a summary reporting requirement.
Reliance Order on Decisions of Foreign Regulatory Authorities
On July 15, 2026, the minister finalized the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs (Reliance Order) under section 30.06 of the Food and Drugs Act (FDA). We previously reported on Health Canada’s draft reliance order consultation.
The Reliance Order allows Health Canada to “deem” the examination of large sections of eligible new drug submission (NDS)—chemistry and manufacturing, non‑clinical, and reliance/or clinical information—to be complete based on a decision from a foreign regulatory authority (FRA) on the same drug. Health Canada would not engage in a substantive review of the information deemed complete, potentially speeding up the approval process. There are also mechanisms for joint review and to file submissions in Canada within 120 days of foreign filing of the same drug to leverage anticipated positive FRA decisions.
The Reliance Order applies to NDS, ANDS, and SNDS/SANDS. Health Canada has published lists of classes of eligible drugs and corresponding FRA for both human drugs (here) and veterinary drugs (here). Existing intellectual protection regimes attached to Health Canada approvals remain in place. Health Canada is also reviewing a draft guidance to accompany the Reliance Order.
Prioritization of generic submissions involving domestic manufacturing
Health Canada sought feedback on a proposed pilot to prioritize the regulatory review of certain generic abbreviated new drug submissions (ANDS) involving domestic manufacturing. The pilot’s objective is to prevent and mitigate potential supply disruptions for Canadian patients in light of increasing submission volumes. The proposed approach would only apply to new generic submissions received after the pilot is implemented.
Other related updates
- The pan-Canada Pharmaceutical Alliance (pCPA) consulted on options to expand its early negotiation (ENP) process to include other products for serious and life-threatening disease, including: (1) Priority Review Drugs; and (2) Advance Consideration under Notice of Compliance with Conditions.
- The Patented Medicine Prices Review Board (PMPRB) published Revised Proposed Practice Directions on procedural matters related to PMPRB hearings. This follows a first consultation that we previously reported on in the spring of 2026. The PMPRB amended the proposed Practice Directions further to stakeholder feedback, including by adjusting default modes of hearing, clarifying document production obligations, and extending page limits. This consultation is open to feedback until September 24, 2026.
- The Pharmaceutical and Life Sciences Sector Task Force released its report to the ministers of health and industry. The task force was announced by the Government of Canada in the spring of 2026 with a mandate to explore how Canada can increase competitiveness and grow a stronger and sustainable domestic pharmaceutical industry. It brought together senior industry leaders and experts. The report identifies main industry challenges, including Canada’s lengthy regulatory pathway to reimbursement and a shortage of domestic late-stage growth capital. The report also makes a series of recommendations to support: (1) regulatory modernization; (2) innovative assessment of value, pricing, and reimbursement; (3) global clinical trial competitiveness; (4) a world-leading AI and health data infrastructure; (5) translational research with improved funding and coordination; (6) scaling Canadian-based life sciences companies; (7) health sovereignty; and (8) system integration, governance, and implementation.